• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human psychopharmacology: clinical and experimental >Nizatidine for the treatment of patients with quetiapine-induced weight gain.
【24h】

Nizatidine for the treatment of patients with quetiapine-induced weight gain.

机译：Nizatidine治疗患者quetiapine-induced体重增加。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It has been reported that nizatidine may reduce weight gain in schizophrenic patients on olanzapine treatment. Leptin has been reported to be associated with antipsychotic-induced weight gain. Thus, the purpose of the study was to evaluate whether nizatidine might be useful for the treatment of quetiapine-induced weight gain. Among the patients on the quetiapine monotherapy, 47 participated in the study for the two and half months of the open-label screening period. However, 28 patients who gained considerable weight in this period entered the 8-week, double-blind and placebo-controlled phase. These patients were randomly divided into two groups; quetiapine plus nizatidine (group I) and quetiapine plus placebo (group II) for the 8-week double-blind phase. The patients were evaluated at the baseline and at week 8 with respect to the positive and negative syndrome scale, body mass index, weight and serum leptin levels. The mean weight and leptin levels exhibited modest increases in both groups for the open-label screening period. In the double-blind period, in group I, a minimal, but not statistically significant, decrease in weight was observed, with a mean of 1.0 +/- 0.6 kg. The weight increased in group II. The leptin levels decreased by a mean of 0.6 +/- 0.6 ng/ml in group I, and increased by 1.0 +/- 0.9 ng/ml in group II. At evaluation at week 8, a trend toward statistical significance in the mean serum leptin levels between groups was detected. The results suggest that nizatidine treatment may stop but not reduce the weight gain and is correlated with leptin levels in patients with schizophrenia on quetiapine treatment.
机译：据报道,nizatidine可能减少精神分裂症患者的体重增加奥氮平治疗。与antipsychotic-induced重量有关收益。评估nizatidine是否可能是有用的治疗quetiapine-induced体重增加。喹硫平单药治疗的患者中,47两个半参与了这项研究个月开放的筛查。然而,28个病人获得可观在这一时期进入8周,双盲,安慰剂对照的阶段。病人被随机分为两组;喹硫平+ nizatidine(我)喹硫平+ 8周的安慰剂(组2)双盲的阶段。在基线和第八周的积极的和消极的综合症,身体质量指数、体重和血清中瘦素的水平。重量和瘦素水平表现出谦虚增加开放的两组筛选期。组我,最小,但不统计重要,观察体重下降,平均值为1.0 + / - 0.6公斤。在第二组中增加。减少了平均0.6 + / - 0.6 ng / ml的组我和增加了1.0 + / - 0.9 ng / ml2统计学意义的意思是血清中瘦素群体之间的水平检测。表明可能停止但nizatidine治疗没有减少体重增加和相关在精神分裂症患者瘦素水平喹硫平治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号